Arcturus Therapeutics (NASDAQ:ARCT) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report released on Monday, Benzinga reports.

Other equities research analysts also recently issued research reports about the stock. William Blair reaffirmed an outperform rating on shares of Arcturus Therapeutics in a research note on Thursday, May 23rd. Leerink Partners began coverage on shares of Arcturus Therapeutics in a research note on Monday, August 12th. They issued an outperform rating and a $70.00 target price for the company. Leerink Partnrs raised shares of Arcturus Therapeutics to a strong-buy rating in a research note on Monday, August 12th. Finally, HC Wainwright upped their target price on shares of Arcturus Therapeutics from $60.00 to $63.00 and gave the company a buy rating in a research note on Thursday, August 8th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Buy and an average target price of $71.40.

Arcturus Therapeutics Price Performance

Shares of NASDAQ ARCT opened at $20.98 on Monday. The company’s 50 day simple moving average is $21.41 and its 200 day simple moving average is $28.12. Arcturus Therapeutics has a fifty-two week low of $17.52 and a fifty-two week high of $45.00. The firm has a market capitalization of $565.03 million, a P/E ratio of -5.37 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The firm had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. During the same quarter in the prior year, the firm earned ($1.98) earnings per share. Sell-side analysts expect that Arcturus Therapeutics will post -2.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

Large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its position in Arcturus Therapeutics by 1.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 186,310 shares of the biotechnology company’s stock valued at $5,874,000 after purchasing an additional 2,369 shares in the last quarter. BNP Paribas Financial Markets grew its position in Arcturus Therapeutics by 3.0% in the fourth quarter. BNP Paribas Financial Markets now owns 23,259 shares of the biotechnology company’s stock valued at $733,000 after purchasing an additional 682 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Arcturus Therapeutics by 11.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock valued at $34,336,000 after purchasing an additional 115,087 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in Arcturus Therapeutics by 9.2% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 41,217 shares of the biotechnology company’s stock valued at $1,300,000 after purchasing an additional 3,457 shares in the last quarter. Finally, Great Lakes Advisors LLC bought a new position in Arcturus Therapeutics in the fourth quarter valued at $6,531,000. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.